VRDN Viridian Therapeutics, Inc.\DE
Pharmaceutical Preparations · Nasdaq · SEC CIK 1590750 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-62.8%
TTM net income YoY-50.2%
TTM EPS YoY—
Revenue 3-yr CAGR323.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,781.4%
Net margin-1,724.1%
FCF margin-1,305.4%
EBITDA margin-1,778.7%
Returns
ROE-83.7%
ROA-56.5%
ROIC (approx.)-97.2%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets43.5%
Debt / equity0.00x
Current ratio14.46x
Interest coverage-19.27x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue7.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $70.85M | $302,000 |
| R&D expense | $338.93M | $238.25M |
| SG&A expense | $95.31M | $61.08M |
| Operating income | -$363.39M | -$299.04M |
| Interest expense | $4.95M | $2.20M |
| Income tax | $0 | — |
| Net income | -$342.60M | -$269.95M |
| EBITDA | -$362.94M | -$298.50M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $212.38M | $99.59M |
| Short-term investments | $662.27M | $617.99M |
| Receivables | $0 | — |
| Inventory | $0 | — |
| Current assets | $894.23M | $738.46M |
| PP&E, net | $1.23M | $1.24M |
| Intangibles | $0 | — |
| Total assets | $899.42M | $742.40M |
| Current liabilities | $70.70M | $47.87M |
| Short-term debt | — | $0 |
| Long-term debt | — | $20.58M |
| Total debt | — | $20.58M |
| Total liabilities | $177.25M | $70.76M |
| Shareholders' equity | $722.17M | $671.64M |
| Net debt | — | -$79.01M |
| Shares outstanding | 101.83M | 80.99M |
| Cash flow statement | ||
| Operating cash flow | -$276.39M | -$232.32M |
| Capital expenditure | $495,000 | $511,000 |
| Free cash flow | -$276.89M | -$232.83M |
| Investing cash flow | -$37.56M | -$228.65M |
| Financing cash flow | $426.74M | $457.74M |
| Depreciation & amortization | $460,000 | $540,000 |
| Stock-based compensation | $44.30M | $42.15M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.